MA52945A - Procédé de production d'un mélange contrôlé d'au moins deux anticorps différents - Google Patents

Procédé de production d'un mélange contrôlé d'au moins deux anticorps différents

Info

Publication number
MA52945A
MA52945A MA052945A MA52945A MA52945A MA 52945 A MA52945 A MA 52945A MA 052945 A MA052945 A MA 052945A MA 52945 A MA52945 A MA 52945A MA 52945 A MA52945 A MA 52945A
Authority
MA
Morocco
Prior art keywords
producing
different antibodies
controlled mixture
mixture
controlled
Prior art date
Application number
MA052945A
Other languages
English (en)
Inventor
Jong Rob De
Arnout Gerritsen
Richard Hibbert
Aran Frank Labrijn
Paul Parren
Janine Schuurman
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab As filed Critical Genmab As
Publication of MA52945A publication Critical patent/MA52945A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA052945A 2018-06-22 2019-06-24 Procédé de production d'un mélange contrôlé d'au moins deux anticorps différents MA52945A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18179365 2018-06-22

Publications (1)

Publication Number Publication Date
MA52945A true MA52945A (fr) 2021-04-28

Family

ID=62841830

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052945A MA52945A (fr) 2018-06-22 2019-06-24 Procédé de production d'un mélange contrôlé d'au moins deux anticorps différents

Country Status (9)

Country Link
US (1) US20210269509A1 (fr)
EP (1) EP3810649A1 (fr)
JP (1) JP2021528435A (fr)
CN (1) CN112513074A (fr)
CA (1) CA3104390A1 (fr)
IL (1) IL279528A (fr)
MA (1) MA52945A (fr)
SG (1) SG11202012713RA (fr)
WO (1) WO2019243626A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023514692A (ja) 2020-02-21 2023-04-07 ジェンマブ ビー．ブイ． 糖蛋白質の定量のための方法
KR20240032959A (ko) * 2021-07-14 2024-03-12 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Hgfr 및 egfr에 특이적으로 결합하는 항원-결합 분자, 및 이의 약학적 용도
WO2024109914A1 (fr) * 2022-11-24 2024-05-30 江苏恒瑞医药股份有限公司 Composition pharmaceutique comprenant un anticorps bispécifique se liant spécifiquement à hgfr et à egfr

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
WO2000005266A1 (fr) 1998-07-21 2000-02-03 Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh Anticorps contre le virus de l'hepatite c et ses utilisations
WO2004009618A2 (fr) * 2002-07-18 2004-01-29 Crucell Holland B.V. Production par recombinaison de melanges d'anticorps
MXPA03011365A (es) 2001-06-13 2005-03-07 Genmab As Anticuerpos monoclonales humanos para el receptor de factor de crecimiento epidermico (egfr).
DK3284753T3 (da) 2002-10-17 2021-07-05 Genmab As Humane monoklonale antistoffer mod cd20 til anvendelse i behandlingen af multipel sclerose
MXPA05006724A (es) 2003-01-07 2005-09-08 Symphogen As Metodo para producir proteinas policlonales recombinantes.
NZ552264A (en) * 2004-07-20 2010-03-26 Symphogen As A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
NZ552265A (en) * 2004-07-20 2009-04-30 Symphogen As Anti-rhesus D recombinant polyclonal antibody and methods of manufacture
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
DK2152872T3 (da) 2007-05-25 2010-12-06 Symphogen As Fremgangsmåde til fremstilling af et rekombinant polyklonalt protein
RU2010147652A (ru) * 2008-04-23 2012-05-27 Симфоген А/С (Dk) Способы производства поликлонального белка
DK2393927T3 (en) 2009-02-09 2015-03-30 Morphosys Ag Preparation of oligoclonal mixtures of antibodies in the individual cells
KR20120027055A (ko) 2009-06-26 2012-03-20 리제네론 파라마큐티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
SG10202001677QA (en) 2010-03-12 2020-04-29 Debiopharm International S A Cd37-binding molecules and immunoconjugates thereof
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
EP2575880B1 (fr) 2010-05-27 2019-01-16 Genmab A/S Anticorps monoclonaux contre l'épitope de her2
DK2640743T3 (en) 2010-11-16 2017-01-23 Excelimmune Inc PROCEDURES FOR THE PREPARATION OF RECOMBINANT PROTEINS
CA2832387A1 (fr) 2011-04-20 2012-10-26 Genmab A/S Anticorps bispecifiques contre her2
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
US10047144B2 (en) 2011-10-19 2018-08-14 Novimmune Sa Methods of purifying antibodies
AU2013234039B2 (en) 2012-03-13 2018-02-01 Novimmune S.A. Readily isolated bispecific antibodies with native immunoglobulin format
EP3401337A1 (fr) 2012-09-25 2018-11-14 Glenmark Pharmaceuticals S.A. Purification d'immunoglobulines hétérodimères
CN113735967A (zh) 2013-01-10 2021-12-03 根马布私人有限公司 人类IgG1 FC区变体及其用途
CA2909969A1 (fr) 2013-05-13 2014-12-31 Medimmune, Llc Separation de multimeres d'anticorps polyclonaux de recombinaison avec une separation minimale des monomeres
RS60012B1 (sr) 2014-07-11 2020-04-30 Genmab As Antitela koja vezuju axl
EP3233907B1 (fr) * 2014-12-19 2021-03-03 Genmab A/S Protéines hétérodimères bispécifiques de rongeurs
IL264631B2 (en) * 2016-08-16 2024-05-01 Regeneron Pharma A method for quantifying individual antibodies from a mixture

Also Published As

Publication number Publication date
EP3810649A1 (fr) 2021-04-28
CA3104390A1 (fr) 2019-12-26
CN112513074A (zh) 2021-03-16
IL279528A (en) 2021-01-31
WO2019243626A1 (fr) 2019-12-26
SG11202012713RA (en) 2021-01-28
US20210269509A1 (en) 2021-09-02
JP2021528435A (ja) 2021-10-21

Similar Documents

Publication Publication Date Title
MA52945A (fr) Procédé de production d'un mélange contrôlé d'au moins deux anticorps différents
MA53673A (fr) Procédé de production d'un dérivé de 4-méthoxy pyrrole
MA48723A (fr) Procédé de production d'anticorps multispécifiques
MA53920A (fr) Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38
MA41200B1 (fr) Procédé pour la préparation d'un composé diarylthiohydantoïne
MA50169A (fr) Procédé de production d'un électrocatalyseur
MA42539A (fr) Mélange pour la construction de produits infrastructuraux et structuraux et procédé de production associé
PH12019502093A1 (en) Novel ester compounds, method for the production thereof and use thereof
BR112018073490A2 (pt) 6.7.beta-epóxidos esteroides como intermediários químicos
MA45768A (fr) Procédé pour la préparation de compositions d'immunoglobulines
MA50170A (fr) Procédé et système de production d'un mélange gazeux
WO2015124764A8 (fr) Procédé de synthèse de dabigatran étexilate mésylate, intermédiaires de ce procédé et nouveau polymorphe de dabigatran étexilate
MA54248A (fr) Régulation de métaux traces pendant la production d'anticorps anti-cd38
MA52755A (fr) Procédé d'enrobage d'engrais
MA56129A (fr) Procédés de production d'un anticorps anti-alpha4béta7
MA51420A (fr) Inoculant de fonte et procédé de production d'un inoculant de fonte
MA50838A (fr) Procédés de production de matieres végétales ensilées à l'aide de megasphaera elsdenii
MA50859A (fr) Procédé pour la production d'une composition de lymphocytes t
MA51913A (fr) Composition granulaire, procédé de production d'une composition granulaire et procédé d'amélioration de la propriété d'élution d'une composition granulaire
MA54299A (fr) Procédés de production de compositions d'allergènes mixtes
MA50983A (fr) Procédé pour la fabrication d'un disque composite
MA51339A (fr) Procédé de préparation de composés pyrimidinyl-4-aminopyrazole
MA49555A (fr) Procédé amélioré de préparation d'imetelstat
MA46790A (fr) Tuile modulaire, latte fonctionnalisée, tuyau et procédé de production d'un tuyau
FR3053331B1 (fr) Procede de production de butadiene a partir d'ethanol integre avec distillation extractive